Form 4 for ALNY ALNYLAM PHARMACEUTICALS, INC.
Accepted 2026-06-03 16:25:20 ET · period of report 2026-06-01 · accession 0001178670-26-000048 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-03 16:25 | 2026-06-01 | ALNY | PYOTT DAVID E I | Dir | M - OptEx | $0.00 | +3,830 | 5,412 | +242% | $0 |
| DMT | 2026-06-03 16:25 | 2026-06-01 | ALNY | PYOTT DAVID E I | Dir | S - Sale+OE | $299.18 | -3,830 | 1,582 | -71% | -$1.15M |
| DT | 2026-06-03 16:25 | 2026-06-01 | ALNY | PYOTT DAVID E I | Dir | M - OptEx | $0.00 | -3,830 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-01 | M | A | 3,830 | $0.00 | 5,412 | D | — | — | (F1) The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. |
| 2 | Common | Common Stock | 2026-06-01 | S | D | 921 | $297.71 | 4,491 | D | — | — | (F1) The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. (F2) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Common | Common Stock | 2026-06-01 | S | D | 1,175 | $298.91 | 3,316 | D | — | — | (F1) The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. (F3) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 4 | Common | Common Stock | 2026-06-01 | S | D | 1,222 | $299.87 | 2,094 | D | — | — | (F1) The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. (F4) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 5 | Common | Common Stock | 2026-06-01 | S | D | 495 | $300.72 | 1,599 | D | — | — | (F1) The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. (F5) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 6 | Common | Common Stock | 2026-06-01 | S | D | 17 | $302.65 | 1,582 | D | — | — | (F1) The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. |
| 7 | Derivative | Stock Option (Right to Buy) | 2026-06-01 | M | D | 3,830 | $0.00 | 0 | D | $70.20 · 2017-06-03 to 2026-06-03 | 3,830 Common Stock | (F1) The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. (F7) This stock option was fully vested and exercisable as of June 3, 2017. |